Showing 15 posts of 18 posts found.


Takeda ordered to pay Bayer $155.19 million over patent infringement

February 6, 2019
Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate

A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of …


Shire shifts vaccine facility from Baxalta deal to MSD

August 8, 2017
Manufacturing and Production Baxalta, MSD, Shire, biotech, drugs, pharma, pharmaceutical

As part of Shire’s mega-merger with Baxalta, it suddenly had a massive manufacturing network that spanned 17 sites across seven …


Shire Q2 results outpace forecasts with 56% revenue growth

August 2, 2016
Research and Development, Sales and Marketing Baxalta, Shire, financial report

Shire has announced its fiscal results for Q2 2016, reporting a strong quarter with a 56% growth in total revenues …

Shire and BMS secure NICE recommendations for oncology drugs

July 27, 2016
Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …


Shire completes Baxalta takeover

June 3, 2016
Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales

UK drugmaker Shire (LSE: SHP) on Friday announced the completion of merger with rare disease specialist Baxalta (NYSE: BXLT).  The …


Baxalta sues Chugai for haemophilia drug patent breach

May 11, 2016
Research and Development Baxalta, Chugai, breach, court, haemophilia, infringe, infringement, patent, sue, suing

Baxalta has taken Chugai Pharmaceuticals to the Tokyo district court, claiming that the Japanese company has infringed upon its patent …


Baxter hikes 2016 earnings view driven by strong Q1 results

April 27, 2016
Research and Development, Sales and Marketing Baxalta, FY, Q1, baxter, earnings, outlook, results, revenue

Baxter International (NYSE: BAX) reported better-than-expected first-quarter profits and raised its earnings outlook for 2016. The company now sees earnings …


Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup

April 7, 2016
Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire

Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …


Baxter to cut stake in Baxalta

March 17, 2016
Business Services, Sales and Marketing Baxalta, Shares, Stake sale, baxter

Baxalta Inc (NYSE: BXLT) said former parent company Baxter International (NYSE: BAX) is set to cut its stake in the …


Onconova says Baxalta ends $565 million drug development deal for rigosertib

March 8, 2016
Manufacturing and Production, Research and Development Baxalta, Onconova Therapeutics, drug development, rigosertib

Onconova Therapeutics says Baxalta has terminated its $565 million agreement to jointly develop the company’s lead drug candidate rigosertib. Baxalta …


Baxalta seeks European marketing rights for haemophilia drug

March 3, 2016
Research and Development, Sales and Marketing Adynovi haemophilia a, Baxalta

Baxalta says it has filed for marketing authorisation for its haemophilia drug Adynovi with European regulators. The European Medicines Agency …

Baxalta logo

Baxalta’s Enbrel biosimilar measures up in late-stage study

January 13, 2016
Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis

Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …

Shire and Baxalta reach $32 billion merger agreement

January 11, 2016
Manufacturing and Production, Sales and Marketing Baxalta, Shire, mergers, mergers and acquisitions

One of the industry’s longest-running M&A sagas has finally reached a conclusion, with Shire and Baxalta announcing a $32 billion …

Baxalta logo

Bayer and Baxalta in separate €1 billion-plus deals

January 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Ascensia diabetes care, Baxalta, Bayer, diabetes, panasonic, symphogen

Baxalta has signed a deal with Symphogen potentially worth as much as €1.4 billion, under which the companies will develop …


Reports: $32bn Shire takeover of Baxalta close to done deal

January 4, 2016
Sales and Marketing Baxalta, Shire, acquisition, merger

The deal may have failed to get over the line in 2015, but reports suggest the mega merger is to …

Latest content